| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 171 |
| 1 | METFORMIN | 154 |
| 2 | METFORMIN ER 500 MG | 154 |
| 3 | METFORMIN ER 750 MG | 154 |
| 4 | ACETAMINOPHEN | 135 |
| 5 | TIRZEPATIDE | 131 |
| 6 | OMEPRAZOLE MAGNESIUM | 127 |
| 7 | IPILIMUMAB | 125 |
| 8 | ASPIRIN | 118 |
| 9 | ASPIRIN 325 MG | 117 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | METHYLENE BLUE | 60 | 0.0380 |
| 1 | GALLIUM GA-68 GOZETOTIDE | 5 | 0.0245 |
| 2 | BRIGATINIB | 62 | 0.0170 |
| 3 | FOSAMPRENAVIR CALCIUM | 2 | 0.0153 |
| 4 | USTEKINUMAB-STBA | 4 | 0.0108 |
| 5 | CARBON DIOXIDE | 1 | 0.0087 |
| 6 | CROVALIMAB | 1 | 0.0083 |
| 7 | NAXITAMAB | 2 | 0.0080 |
| 8 | SEVOFLURANE | 64 | 0.0076 |
| 9 | I. V. FAT EMULSION | 4 | 0.0055 |
| # | Drug class | Count |
|---|---|---|
| 0 | GLP-1 Receptor Agonist [EPC] | 360 |
| 1 | Corticosteroid [EPC] | 323 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 302 |
| 3 | Kinase Inhibitor [EPC] | 245 |
| 4 | Proton Pump Inhibitor [EPC] | 204 |
| 5 | Benzodiazepine [EPC] | 196 |
| 6 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 171 |
| 7 | Platinum-based Drug [EPC] | 140 |
| 8 | CTLA-4-directed Blocking Antibody [EPC] | 136 |
| 9 | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | 131 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Complement C5 Inhibitor [EPC] | 1 | 0.0083 |
| 1 | Protease Activator [EPC] | 1 | 0.0078 |
| 2 | Tetracycline-class Antibacterial [EPC] | 35 | 0.0045 |
| 3 | CD123 Interaction [EPC] | 2 | 0.0037 |
| 4 | Vasoconstrictor [EPC] | 1 | 0.0033 |
| 5 | CTLA-4-directed Blocking Antibody [EPC] | 136 | 0.0028 |
| 6 | CD30-directed Immunoconjugate [EPC] | 25 | 0.0024 |
| 7 | Asparagine-specific Enzyme [EPC] | 31 | 0.0023 |
| 8 | Lipid Emulsion [EPC] | 6 | 0.0023 |
| 9 | mu-Opioid Receptor Agonist [EPC] | 6 | 0.0020 |